Issue: Exclusive Online Content, Posted Date: 2/10/2017
Pharma & Biotech: 2017 Review of Outsourced Manufacturing
I am pleased to introduce
you to our 2017 review of the outsourced manufacturing sector, where we share
some of the trends observed in recent years and look to the future of the
industry. In the last five years, the industry has enjoyed positive growth and there
are certainly positive indications for the future. The team at Results Healthcare
has been very busy serving a range of client needs, helping both buyers and
sellers to achieve their strategic goals. We have grown and broadened the healthcare
team in response to the firm’s clients’ demands.
2016 ended with uncertainties
concerning the future of ‘Obamacare’ under the incoming US administration and
debates on the outcome of the British referendum on membership of the European
Union (EU) as well as the performance of the Chinese and broader Asian
economies in 2017. Regulators including the Food and Drug Administration (FDA)
have shown a tougher stance regarding pharmaceutical manufacturers, which has
disproportionately affected Asian suppliers. In May 2016, the EU agreed new
stricter rules on medical devices and in vitro diagnostic medical devices.
Industry leaders need to maintain their awareness of these issues as the
marketplace seems likely to continue to become ever more stringently regulated,
providing opportunities as well as threats. The healthcare providers,
entrepreneurs and their suppliers will need to navigate through relevant changes,
however, we remain very positive for the short and long term.
Looking towards the
future, there are strong indications of above GDP growth for the outsourced
manufacturing sector, which we discuss in this report. This is driven by
greater demand for manufactured product as well as an anticipated rise in
outsourcing. This climate will continue to create opportunities for deals,
M&A and consolidation in the sector. Click here to see the full report.
This record has been viewed 236 times.